Gemifibrozil

Gemfibrozil is the generic name for an oral drug used to lower lipid levels. It belongs to a group of drugs known as fibrates. It is most commonly sold as the brand name, Lopid. Other brand names include Jezil and Gen-Fibro.

Gemifibrozil

NA

Gempar, Lipizyl, Lopid, Losterol, Normolip, Triglyd

5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid

Well absorbed from GI.

Gemfibrozil, a fibric acid antilipemic agent similar to clofibrate, is used to treat hyperlipoproteinemia and as a second-line therapy for type IIb hypercholesterolemia. It acts to reduce triglyceride levels, reduce VLDL levels, reduce LDL levels (moderately), and increase HDL levels (moderately).

1.2 g daily in 2 divided doses oral.

For treatment of adult patients with very high elevations of serum triglyceride levels 

Bone marrow hypoplasia; intracranial haemorrhage; nephrotoxicity; peripheral neuritis. Myositic syndrome, cholelithiasis, GI disturbances, rash, headache, blood dyscrasias, myalgia. Impotence, painful extremities, blurred vision; pruritus, urticaria; impotence; dizziness; cholestatic jaundice.

• Increased risk of myopathy and rhabdomyolysis when used with HMG-CoA reductase inhibitors.
• Co-admin with repaglinide may increase serum levels of repaglinide.
• May enhance effects of oral anticoagulants.
• May also increase the plasma concentrations of ciclosporin and associated nephrotoxicity when used concurrently.

Hypersensitivity. Severe hepatic or renal dysfunction; gall stones; neonates, children, pregnancy, lactation.

Store below 30°C.

Molecular weight

250.3334

Molecular formula

C15H22O3

CAS number

25812-30-0

Precautions

Causes of secondary hyperlipidaemia such as hypothyroidism and diabetes must be treated before initiating therapy. Renal impairment; blood disorders. Periodic monitoring of the serum lipids should be done; if no adequate response after 3 mth, treatment should be withdrawn. May increase risk of cholelithiasis.